Skip to content

Takeda Pharmaceutical

US · TAK #400 by market cap Listed 1970
21.77 +0.36 +1.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
  • Total institutional ownership fell 1.2 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
51.33% -1.15pp
Institutions
728 -2
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund45.36%
Public Company1.76%
Sovereign Wealth Fund1.29%
Private Company1.28%
Hedge Fund0.85%
Government Pension Fund0.53%
Insurance Company0.20%
Individual/Insider0.12%
Other48.58%

Top holders as of 2026-10-15

BlackRock 9.21% · 294.17M sh
Nomura Asset Management 4.40% · 140.69M sh
Vanguard Capital Management, LLC 3.93% · 125.50M sh
Sumitomo Mitsui Trust Asset Management 3.11% · 99.22M sh
Capital Research 3.00% · 95.78M sh
Other 77.08%
Amova Asset Management 2.14% · 68.46M sh
Daiwa Asset Management 2.00% · 63.87M sh
Nissay Asset Management Corporation 1.55% · 49.50M sh
Sumitomo Mitsui Financial Group, Inc. 1.51% · 48.10M sh
Norges Bank Investment Management 1.29% · 41.31M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 19 buys · 31 sells

NameRoleStake
Christophe P. Weber Former President, CEO & Representative Director 0.05%
Andrew S. Plump President of Research & Development and Representative Director 0.02%
Julie Kim Chief Executive Officer 0.01%
Giles Platford President of International Business Unit 0.01%
Teresa Marie Bitetti President of the Global Oncology Business Unit 0.00%
Marcello Pignagnoli Agosti Interim Head of Strategy & Portfolio Development 0.00%
Gabriele Ricci Chief Data & Technology Officer 0.00%
Lauren Duprey Chief Transformation Officer 0.00%
Milano Furuta Chief Financial Officer 0.00%
Farajallah Awny Botros Chief Medical Officer 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-03 Giles Platford President of International Business Unit Open Market Disposition -55,617 $20.90
2026-11-01 Teresa Marie Bitetti President of the Global Oncology Business Unit Private Disposition -46,609 $0.13
2026-10-31 Giles Platford President of International Business Unit Intent to Sell (Form 144) -55,617 $20.17
2026-09-13 Lauren Duprey Chief Transformation Officer Open Market Disposition -34,535 $18.54
2026-09-01 Andrew S. Plump President of Research & Development and Representative Director Automatic Disposition -116,191 $18.49
2026-08-18 Andrew S. Plump President of Research & Development and Representative Director Automatic Disposition -19,651 $18.49
2026-08-17 Nicola Greenway -- Open Market Disposition -12,980 $18.11
2026-08-13 Nicola Greenway -- Intent to Sell (Form 144) -12,980 $17.39
2026-08-10 Elaine Shannon President of Global Supply & Quality Open Market Disposition -20,363 $17.55
2026-08-09 Andrew S. Plump President of Research & Development and Representative Director Private Disposition -165,393 $17.10
2026-08-09 Giles Platford President of International Business Unit Private Disposition -31,083 $17.10
2026-08-09 Farajallah Awny Botros Chief Medical Officer Private Disposition -14,006 $17.10
2026-08-09 Julie Kim Chief Executive Officer Private Disposition -89,090 $17.10
2026-08-09 Teresa Marie Bitetti President of the Global Oncology Business Unit Private Disposition -50,012 $17.10
2026-08-09 Ramy Ibrahim -- Private Disposition -7,277 $17.10
2026-08-09 Lauren Duprey Chief Transformation Officer Private Disposition -47,586 $17.10
2026-08-09 Gabriele Ricci Chief Data & Technology Officer Private Disposition -25,088 $17.10
2026-08-09 Marcello Pignagnoli Agosti Interim Head of Strategy & Portfolio Development Private Disposition -22,957 $17.10
2026-08-09 Elaine Shannon President of Global Supply & Quality Private Disposition -3,978 $17.10
2026-08-09 Natalie Furney Global General Counsel Private Disposition -30,868 $17.10

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Takeda Pharmaceutical discussion 0 comments

Add a comment